Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. (Q45918441)
Jump to navigation
Jump to search
scientific article published on 27 July 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. |
scientific article published on 27 July 2009 |
Statements
1 reference
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. (English)
1 reference
Hans Gelderblom
1 reference
Jaap Verweij
1 reference
Ferry A L M Eskens
1 reference
Neeltje Steeghs
1 reference
Johan L Bloem
1 reference
Olaf Christensen
1 reference
Leni van Doorn
1 reference
Jan Ouwerkerk
1 reference
Maja J A de Jonge
1 reference
Johan W R Nortier
1 reference
Joern Kraetzschmar
1 reference
Prabhu Rajagopalan
1 reference
27 July 2009
1 reference
1 reference
27
1 reference
25
1 reference
4169-4176
1 reference
Identifiers
1 reference
1 reference